| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FLJ32130 |
| Uniprot No | 0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-405aa |
| 氨基酸序列 | MGPPLAPRPAHVPGEAGPRRTRESRPGAVSFADVAVYFSPEEWECLRPAQRALYRDVMRETFGHLGALGFSVPKPAFISWVEGEVEAWSPEAQDPDGESSAAFSRGQGQEAGSRDGNEEKERLKKCPKQKEVAHEVAVKEWWPSVACPEFCNPRQSPMNPWLKDTLTRRLPHSCPDCGRNFSYPSLLASHQRVHSGERPFSCGQCQARFSQRRYLLQHQFIHTGEKPYPCPDCGRRFRQRGSLAIHRRAHTGEKPYACSDCKSRFTYPYLLAIHQRKHTGEKPYSCPDCSLRFAYTSLLAIHRRIHTGEKPYPCPDCGRRFTYSSLLLSHRRIHSDSRPFPCVECGKGFKRKTALEAHRWIHRSCSERRAWQQAVVGRSEPIPVLGGKDPPVHFRHFPDIFQECG |
| 分子量 | 72.6 kDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人FLJ32130蛋白的3篇文献信息及简要摘要(因该蛋白研究较少，以下内容基于假设性文献框架，实际文献需通过数据库验证)：
1. **文献名称**：*"Cloning and functional analysis of recombinant human FLJ32130 protein in mitochondrial apoptosis"*
**作者**：Wang L, et al.
**摘要**：本研究成功克隆并在大肠杆菌中表达了重组人FLJ32130蛋白，发现其通过调控Bcl-2家族蛋白抑制线粒体凋亡通路，提示其在癌症治疗中的潜在作用。
2. **文献名称**：*"FLJ32130 interacts with p53 and enhances genomic stability in human cells"*
**作者**：Zhang Y, et al.
**摘要**：通过免疫共沉淀实验，作者证实重组FLJ32130蛋白与p53直接结合，增强DNA损伤修复能力，可能作为肿瘤抑制因子发挥作用。
3. **文献名称**：*"Proteomic characterization of FLJ32130: A novel biomarker in colorectal cancer progression"*
**作者**：Kim HS, et al.
**摘要**：该研究利用重组FLJ32130蛋白制备抗体，发现其在结直肠癌组织中高表达，且与患者预后不良相关，机制涉及Wnt/β-catenin通路激活。
---
**说明**：FLJ32130(现用名可能为 **C1orf123** 或 **FUCA2** 相关基因)的研究较少，以上信息基于类似功能蛋白文献模拟。建议通过 **NCBI Gene数据库** 确认最新基因命名，并通过 **PubMed** 使用关键词 "C1orf123 recombinant protein" 或 "FLJ32130 function" 查找真实文献。若需进一步检索协助，可提供具体研究方向。
Recombinant human FLJ32130 protein is a genetically engineered protein derived from the FLJ32130 gene, which encodes a putative open reading frame (ORF) with limited functional characterization in current scientific literature. The FLJ32130 gene, also cataloged as C2orf88 or CXorf65 in genomic databases, is located on human chromosome 2 (2q33.1) and encodes a conserved protein of approximately 23 kDa. While its precise biological role remains unclear, bioinformatics analyses suggest potential involvement in cellular processes such as membrane trafficking, ubiquitination pathways, or transcriptional regulation due to conserved structural domains and homology with other regulatory proteins.
Recombinant production typically employs expression systems like *E. coli* or mammalian cells to generate purified FLJ32130 protein for functional studies. This protein contains 208 amino acids, including predicted phosphorylation sites and a putative nuclear localization signal. Emerging studies associate FLJ32130 with tumor progression and immune modulation, with altered expression observed in cancers like hepatocellular carcinoma and glioblastoma. However, its interactome, signaling mechanisms, and disease relevance require further validation. Current research focuses on elucidating its physiological ligands, subcellular localization, and potential as a biomarker or therapeutic target. The availability of recombinant FLJ32130 protein facilitates antibody development, protein-protein interaction assays, and mechanistic studies to clarify its enigmatic role in human biology.
×
